BRPI0517128A - composições de combate à resistência a antibióticos, métodos de tratamento e processos de preparação de composição - Google Patents

composições de combate à resistência a antibióticos, métodos de tratamento e processos de preparação de composição

Info

Publication number
BRPI0517128A
BRPI0517128A BRPI0517128-8A BRPI0517128A BRPI0517128A BR PI0517128 A BRPI0517128 A BR PI0517128A BR PI0517128 A BRPI0517128 A BR PI0517128A BR PI0517128 A BRPI0517128 A BR PI0517128A
Authority
BR
Brazil
Prior art keywords
compositions
normally
sodium
gives
sulbactam
Prior art date
Application number
BRPI0517128-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Manu Chaudhary
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of BRPI0517128A publication Critical patent/BRPI0517128A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
BRPI0517128-8A 2004-12-02 2005-11-28 composições de combate à resistência a antibióticos, métodos de tratamento e processos de preparação de composição BRPI0517128A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2411DE2004 2004-12-02
PCT/IN2005/000382 WO2006059344A1 (en) 2004-12-02 2005-11-28 Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection

Publications (1)

Publication Number Publication Date
BRPI0517128A true BRPI0517128A (pt) 2008-09-30

Family

ID=35789266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517128-8A BRPI0517128A (pt) 2004-12-02 2005-11-28 composições de combate à resistência a antibióticos, métodos de tratamento e processos de preparação de composição

Country Status (23)

Country Link
US (2) US8273732B2 (cg-RX-API-DMAC7.html)
EP (1) EP1841432B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269415B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070067189A (cg-RX-API-DMAC7.html)
CN (1) CN101060846A (cg-RX-API-DMAC7.html)
AT (1) ATE476981T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005310888B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517128A (cg-RX-API-DMAC7.html)
CY (1) CY1110886T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022939D1 (cg-RX-API-DMAC7.html)
DK (1) DK1841432T3 (cg-RX-API-DMAC7.html)
ES (1) ES2349301T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100591T1 (cg-RX-API-DMAC7.html)
MX (1) MX2007006540A (cg-RX-API-DMAC7.html)
NZ (1) NZ555075A (cg-RX-API-DMAC7.html)
PL (1) PL1841432T3 (cg-RX-API-DMAC7.html)
PT (1) PT1841432E (cg-RX-API-DMAC7.html)
RS (1) RS51506B (cg-RX-API-DMAC7.html)
RU (1) RU2397768C2 (cg-RX-API-DMAC7.html)
SI (1) SI1841432T1 (cg-RX-API-DMAC7.html)
UA (1) UA91204C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006059344A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704394B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030010176A (ko) * 2001-07-25 2003-02-05 이병두 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
AU2011369802B2 (en) * 2011-05-28 2016-09-08 Wockhardt Limited Compositions comprising antibacterial agent and tazobactam
WO2013014497A1 (en) * 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
SG11201405799TA (en) 2012-03-26 2014-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN105025901B (zh) * 2012-09-27 2019-04-19 默沙东公司 他唑巴坦精氨酸抗生素组合物
WO2015126989A1 (en) 2014-02-18 2015-08-27 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
CN106900171A (zh) * 2014-03-29 2017-06-27 沃克哈特有限公司 包含头孢吡肟或舒巴坦的药物组合物
BR112016021720B1 (pt) * 2014-04-03 2021-09-28 Baxter International Incorporated Bolsa de injeção e conjunto de preparação de injeção
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
EP3429592A4 (en) * 2016-11-02 2019-10-30 Xiangbei Welman Pharmaceutical Co., Ltd COMPOSITION OF CEFTRIAXONNATRIUM AND SULBACTUMNATRIUM
CN106822147B (zh) * 2016-11-03 2021-07-20 湘北威尔曼制药股份有限公司 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用
RU2665006C1 (ru) * 2017-02-28 2018-08-24 Общество с ограниченной ответственностью "Супербаг Солюшенс" Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
PL3833665T3 (pl) 2018-08-09 2023-12-27 Antabio Sas Diazabicykloktanony jako inhibitory beta-laktamaz serynowych
US12228578B2 (en) 2020-12-17 2025-02-18 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
WO2025165952A1 (en) * 2024-01-31 2025-08-07 The Penn State Research Foundation Process for reduction of drug-resistant bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Also Published As

Publication number Publication date
RU2007124325A (ru) 2009-01-10
RS51506B (sr) 2011-06-30
EP1841432B1 (en) 2010-08-11
JP2008521884A (ja) 2008-06-26
PL1841432T3 (pl) 2011-01-31
KR101244362B1 (ko) 2013-03-18
HRP20100591T1 (hr) 2010-12-31
PT1841432E (pt) 2010-10-25
US20130023512A1 (en) 2013-01-24
NZ555075A (en) 2011-02-25
ATE476981T1 (de) 2010-08-15
EP1841432A1 (en) 2007-10-10
MX2007006540A (es) 2008-01-31
US20100160277A1 (en) 2010-06-24
UA91204C2 (ru) 2010-07-12
US8273732B2 (en) 2012-09-25
ZA200704394B (en) 2008-09-25
AU2005310888B2 (en) 2011-01-06
RU2397768C2 (ru) 2010-08-27
DE602005022939D1 (de) 2010-09-23
WO2006059344B1 (en) 2006-11-02
KR20070067189A (ko) 2007-06-27
DK1841432T3 (da) 2010-12-06
AU2005310888A1 (en) 2006-06-08
SI1841432T1 (sl) 2011-02-28
CN101060846A (zh) 2007-10-24
KR20090101514A (ko) 2009-09-28
ES2349301T3 (es) 2010-12-29
US9012442B2 (en) 2015-04-21
JP5269415B2 (ja) 2013-08-21
WO2006059344A1 (en) 2006-06-08
CY1110886T1 (el) 2015-06-10

Similar Documents

Publication Publication Date Title
ZA200704394B (en) Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection
JP7245289B2 (ja) 細菌感染症の処置方法
JP2018138578A5 (cg-RX-API-DMAC7.html)
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
WO2007112000A3 (en) Treatment of pain
WO2006117240A3 (en) Novel method for preventing or treating m tuberculosis infection
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
CN101080221A (zh) 抗药性细菌感染疾病的肠胃外综合治疗
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
JP2023012538A (ja) 細菌感染症を処置する方法
TW200639159A (en) Treatment of pain
Hamdy et al. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理
ATE376422T1 (de) Diclazurilhaltige antiprotozoenmittel
EA200600377A1 (ru) Новая композиция
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
Monogue et al. Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection
RU2006119263A (ru) Способ лечения больных розацеа
CN1709263A (zh) 抗菌素组合物
WO2022177968A8 (en) Therapeutic methods
WO2022161554A4 (es) Composición farmacéutica que comprende el ghrp-6
TW200618812A (en) Compositions containing piperacillin and tazobactam useful for injection
NZ795891A (en) Methods of treating bacterial infections

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.